2026-06-24

Cocoa bull 9.6% vs prior close ($4,545.00 → $4,982.00)

Silver volume spike - 3.2× the 20-day average (294 vs 91 avg)

Platinum volume spike - 12.4× the 20-day average (148 vs 11 avg)

RBOB Gasoline bear 6.0% vs prior close ($2.96 → $2.78)

Silver bear 7.2% vs prior close ($62.02 → $57.57)

OSINT: Escalating Ukraine Geopolitical Tensions Raise Market Risk

Gold -2.75%: significant decline on the session

Oil -4.40%: significant decline on the session

OSINT: Iran Deploys 6,200‑ton Offshore Oil Platform in Persian Gulf

Gold -2.60%: significant decline on the session

Oil -4.02%: significant decline on the session

OSINT: Russia's MAGN entity hit by new sanctions, market eyes impact

OSINT: Canadian Dollar Down 30% vs USD Since GFC

Platinum bear 4.6% vs prior close ($1,660.90 → $1,585.00)

WTI Crude Oil bear 4.6% vs prior close ($73.21 → $69.86)

Sugar No. 11 bull 4.4% vs prior close ($13.42 → $14.01)

GOLD RSI 29.2 - oversold (crossed below 30)

BTC ETF inflow of $2123M - institutional buying

ETH ETF inflow of $379M - institutional buying

BTC open interest -67.4% - OI collapse

SOL open interest +244.7% - OI surge

ETH open interest +208.2% - OI surge

ETH open interest +228.0% - OI surge

BTC open interest +90.5% - OI surge

SOL open interest -57.4% - OI collapse

BITCOIN - speculators net long (+2.5σ vs 52w mean) - contrarian bear signal

SPYx/USDC has $116.9M 24h volume on $1174K liquidity (100x turnover): thin market, elevated slippage

SPYx/USDC has $92.7M 24h volume on $1612K liquidity (57x turnover): thin market, elevated slippage

ETH open interest +200.1% - OI surge

BTC open interest -39.6% - OI collapse

SOL open interest +136.4% - OI surge

SOL open interest +133.1% - OI surge

BTC open interest +213.1% - OI surge

ETH open interest -66.6% - OI collapse

SOL DEX volume/liquidity ratio elevated (1.25x): on-chain trade volume 1.25x liquidity

SOL DEX volume/liquidity ratio elevated (0.98x): on-chain trade volume 0.98x liquidity

Phase 3 trial terminated early - ELI A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY30

Phase 3 trial terminated early - ELI A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 Wit

Phase 3 trial terminated early - BRISTOL Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-h

Phase 3 trial terminated early - BRISTOL Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study

Phase 3 trial terminated early - BRISTOL A Study of Vinflunine in Patients With Gastric Cancer

Phase 3 trial terminated early - BIOGEN A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in

Phase 3 trial terminated early - AMGEN Impact of LDL-cholesterol Lowering on Platelet Activation

Phase 3 trial terminated early - AbbVie Study Of Diabetic Nephropathy With Atrasentan

Phase 3 trial terminated early - Merck Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Tre

Phase 3 trial terminated early - Merck Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IF

Phase 3 trial terminated early - Merck Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (I

Phase 3 trial terminated early - Merck Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monoth

Phase 3 trial terminated early - PFIZER Effects of Atorvastatin on Myonecrosis

Phase 3 trial terminated early - PFIZER Gabapentin for the Treatment of Neuroleptic-Induced Tremor

Phase 3 trial terminated early - PFIZER Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavi

Phase 3 trial terminated early - PFIZER A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of

Phase 3 trial terminated early - PFIZER Ziprasidone And Olanzapine's Outcomes In Mania

Phase 3 trial terminated early - PFIZER Study Evaluating The Safety Of Xyntha In Usual Care Settings

Phase 3 trial terminated early - PFIZER Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine

Phase 3 trial terminated early - GILEAD Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Phase 3 trial terminated early - GILEAD ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associ

HARTFORD INSURANCE GROUP, INC. search volume spiked +100 pts - unusual interest

Callaway Golf Co search volume spiked +100 pts - unusual interest

People Inc search volume spiked +25 pts - unusual interest

Q2-2025: Missed consensus by 17.1% - EPS $47.75 vs $57.57 estimate

Q1-2025: Beat consensus by 193.3% - EPS $13.19 vs $-14.14 estimate

Q4-2024: Missed consensus by 52.4% - EPS $-50.78 vs $-33.33 estimate

Q3-2024: Missed consensus by 30.3% - EPS $69.68 vs $99.99 estimate

Q3-2025: Missed consensus by 375.2% - EPS $-0.48 vs $-0.101 estimate

Q1-2026: Beat consensus by 6.1% - EPS $3.22 vs $3.034 estimate

Q2-2023: Beat consensus by 21.6% - EPS $-6 vs $-7.65 estimate

Q1-2023: Missed consensus by 17.6% - EPS $-9 vs $-7.65 estimate

Q4-2022: Missed consensus by 7.8% - EPS $-16.5 vs $-15.3 estimate

Q3-2023: Beat consensus by 26.5% - EPS $-4.5 vs $-6.12 estimate

Q4-2025: Missed consensus by 28.4% - EPS $-1.7009 vs $-1.3251 estimate

Q1-2026: Missed consensus by 42.8% - EPS $-0.3462 vs $-0.2425 estimate

Q3-2025: Missed consensus by 33.9% - EPS $0.16 vs $0.242 estimate

Q1-2026: Missed consensus by 53.3% - EPS $-0.48 vs $-0.3131 estimate

Q2-2026: Beat consensus by 19.8% - EPS $0.52 vs $0.434 estimate

Q3-2025: Beat consensus by 8.1% - EPS $-0.5 vs $-0.544 estimate

Q4-2025: Missed consensus by 194.1% - EPS $-0.15 vs $-0.051 estimate

Q4-2025: Missed consensus by 139.2% - EPS $-0.44 vs $1.122 estimate

Q2-2025: Missed consensus by 21.6% - EPS $0.76 vs $0.969 estimate

Q3-2025: Beat consensus by 41.2% - EPS $-0.15 vs $-0.255 estimate

Q2-2025: Missed consensus by 5.0% - EPS $-0.3 vs $-0.2856 estimate

Q1-2026: Missed consensus by 13.8% - EPS $1.65 vs $1.9133 estimate

Q1-2026: Missed consensus by 27.9% - EPS $1.24 vs $1.7209 estimate

Q4-2024: Missed consensus by 272.5% - EPS $-1.14 vs $-0.306 estimate

Q2-2024: Missed consensus by 7.7% - EPS $-0.714 vs $-0.663 estimate

Q1-2026: Missed consensus by 13.7% - EPS $2.21 vs $2.56 estimate

Q4-2025: Beat consensus by 19.9% - EPS $-0.94 vs $-1.173 estimate

Q1-2026: Missed consensus by 172.4% - EPS $-1.45 vs $-0.5324 estimate

Q4-2024: Beat consensus by 1082.0% - EPS $95.66 vs $-9.741 estimate

Q4-2025: Missed consensus by 12.9% - EPS $0.08 vs $0.0918 estimate

Q1-2026: Missed consensus by 11.8% - EPS $0.09 vs $0.102 estimate

Q1-2026: Missed consensus by 10.7% - EPS $0.15 vs $0.168 estimate

Q2-2025: Beat consensus by 54.0% - EPS $0.69 vs $0.448 estimate

Q4-2025: Beat consensus by 135.6% - EPS $0.257 vs $-0.721 estimate

Q2-2025: Beat consensus by 196.7% - EPS $4.02 vs $1.355 estimate

Q3-2026: Missed consensus by 51.9% - EPS $-0.12 vs $-0.079 estimate

Q2-2025: Missed consensus by 10.1% - EPS $0.25 vs $0.278 estimate

Q3-2023: Missed consensus by 194.1% - EPS $-36000 vs $-12240 estimate

Q4-2023: Beat consensus by 14.2% - EPS $-10500 vs $-12240 estimate

Q1-2024: Beat consensus by 21.6% - EPS $-24000 vs $-30600 estimate

Q2-2024: Beat consensus by 66.2% - EPS $-9300 vs $-27540 estimate

Q1-2026: Missed consensus by 8.1% - EPS $0.2 vs $0.2176 estimate

Q3-2026: Beat consensus by 15.7% - EPS $4.1 vs $3.544 estimate

Q2-2025: Beat consensus by 42.6% - EPS $-54.24 vs $-94.536 estimate

Q1-2026: Beat consensus by 17.4% - EPS $1.02 vs $0.869 estimate

Q2-2025: Beat consensus by 226.1% - EPS $0.18 vs $-0.1428 estimate

Q1-2026: Missed consensus by 17.6% - EPS $-0.16 vs $-0.136 estimate

Q1-2027: Beat consensus by 2174.5% - EPS $1.16 vs $0.051 estimate

Q2-2026: Beat consensus by 143.0% - EPS $0.92 vs $-2.142 estimate

Q2-2025: Beat consensus by 62.6% - EPS $0.47 vs $0.289 estimate

Q4-2024: Missed consensus by 81.6% - EPS $-0.25 vs $-0.1377 estimate

Q3-2025: Beat consensus by 5.7% - EPS $0.84 vs $0.795 estimate

Q3-2025: Beat consensus by 6.9% - EPS $-0.46 vs $-0.494 estimate

Q2-2025: Missed consensus by 11.2% - EPS $2.96 vs $3.333 estimate

Q1-2009: Missed consensus by 21.9% - EPS $31.5704 vs $40.4 estimate

Q1-2008: Missed consensus by 32.4% - EPS $0.3182 vs $0.471 estimate

Q4-2008: Beat consensus by 31.6% - EPS $42.528 vs $32.32 estimate

Q4-2025: Missed consensus by 909.5% - EPS $-28.55 vs $-2.828 estimate

Q2-2026: Beat consensus by 10.5% - EPS $31.79129 vs $28.78 estimate

Q4-2025: Beat consensus by 7.4% - EPS $1.76 vs $1.639 estimate

Q4-2025: Missed consensus by 23.3% - EPS $-0.28 vs $-0.227 estimate

Q1-2026: Beat consensus by 17.6% - EPS $0.36 vs $0.306 estimate

Q2-2025: Beat consensus by 29.5% - EPS $0.58 vs $0.448 estimate

Q4-2025: Missed consensus by 11.3% - EPS $0.19 vs $0.2142 estimate

Q1-2026: Beat consensus by 143.6% - EPS $2.09 vs $0.858 estimate

Q1-2015: Missed consensus by 154.9% - EPS $-299520 vs $-117504 estimate

Q2-2017: Missed consensus by 96.1% - EPS $-92160 vs $-47001.6 estimate

Q4-2017: Missed consensus by 426.8% - EPS $-230400 vs $70502.4 estimate

Q4-2025: Beat consensus by 27.7% - EPS $0.82 vs $0.642 estimate

Q1-2026: Beat consensus by 20.8% - EPS $-0.35 vs $-0.442 estimate

Q1-2026: Beat consensus by 28.7% - EPS $2.68 vs $2.082 estimate

Q1-2022: Missed consensus by 19.7% - EPS $2.48 vs $3.09 estimate

Q2-2022: Missed consensus by 23.0% - EPS $2.3 vs $2.987 estimate

Q4-2026: Beat consensus by 14.5% - EPS $3.82 vs $3.336 estimate

Q2-2026: Beat consensus by 24.4% - EPS $2.52 vs $2.025 estimate

Q3-2026: Beat consensus by 9.6% - EPS $2.83 vs $2.581 estimate

Q3-2025: Beat consensus by 83.9% - EPS $-0.02 vs $-0.1242 estimate

Q1-2026: Beat consensus by 56.9% - EPS $0.16 vs $0.102 estimate

Q4-2023: Missed consensus by 102.3% - EPS $-57.25 vs $-28.305 estimate

Q3-2024: Missed consensus by 79.2% - EPS $-13.25 vs $-7.395 estimate

Q2-2024: Beat consensus by 52.9% - EPS $-9.25 vs $-19.635 estimate

Q1-2024: Missed consensus by 15.1% - EPS $-42.25 vs $-36.72 estimate

Q2-2025: Beat consensus by 71.7% - EPS $-6 vs $-21.21 estimate

Q2-2025: Beat consensus by 6.8% - EPS $-0.55 vs $-0.59 estimate

Q1-2025: Missed consensus by 73.6% - EPS $0.08 vs $0.303 estimate

Q4-2025: Missed consensus by 786.1% - EPS $-1.79 vs $-0.202 estimate

Q3-2025: Beat consensus by 55.9% - EPS $-0.09 vs $-0.204 estimate

Q1-2026: Beat consensus by 15.0% - EPS $-0.13 vs $-0.153 estimate

Q2-2025: Beat consensus by 11.8% - EPS $-0.21 vs $-0.238 estimate

Q3-2025: Missed consensus by 117.8% - EPS $-0.11 vs $-0.0505 estimate

Q2-2025: Missed consensus by 177.2% - EPS $-0.14 vs $-0.0505 estimate

Q3-2025: Beat consensus by 10.1% - EPS $0.25 vs $0.227 estimate

Q1-2026: Beat consensus by 174.5% - EPS $1.4 vs $0.51 estimate

Q1-2027: Beat consensus by 25.4% - EPS $0.32 vs $0.2552 estimate

Q4-2025: Beat consensus by 9.9% - EPS $1.56 vs $1.419 estimate

Q3-2025: Beat consensus by 14.2% - EPS $-1.75 vs $-2.04 estimate

Q1-2025: Beat consensus by 61.8% - EPS $-7.5 vs $-19.635 estimate

Q2-2025: Missed consensus by 6.6% - EPS $-6.25 vs $-5.865 estimate

Q4-2025: Missed consensus by 68.0% - EPS $-2.57 vs $-1.53 estimate

Q2-2025: Missed consensus by 6.8% - EPS $0.2 vs $0.2146 estimate

Q3-2025: Beat consensus by 32.9% - EPS $1.38 vs $1.038 estimate

Q2-2025: Beat consensus by 24.5% - EPS $0.91 vs $0.731 estimate

Q4-2025: Beat consensus by 12.0% - EPS $0.1736 vs $0.155 estimate

Q2-2025: Beat consensus by 5.3% - EPS $2.77 vs $2.631 estimate

Q2-2026: Beat consensus by 243.1% - EPS $1.4 vs $0.408 estimate

Q2-2025: Beat consensus by 44.6% - EPS $0.97 vs $0.671 estimate

Q2-2026: Missed consensus by 5.9% - EPS $0.43 vs $0.4569 estimate

Q1-2026: Missed consensus by 684.3% - EPS $-0.44 vs $-0.0561 estimate

Q1-2026: Beat consensus by 10.4% - EPS $1.65 vs $1.4947 estimate

Q3-2026: Missed consensus by 99.8% - EPS $0.0501 vs $20.6871 estimate

Q2-2026: Missed consensus by 99.0% - EPS $0.16 vs $15.6468 estimate

Q4-2025: Missed consensus by 29.8% - EPS $-0.27007 vs $-0.208 estimate

Q1-2026: Missed consensus by 50.2% - EPS $-0.33998 vs $-0.2264 estimate

Q1-2026: Beat consensus by 284.1% - EPS $0.71 vs $-0.3856 estimate

Q4-2026: Beat consensus by 13.3% - EPS $-4.83 vs $-5.5692 estimate

Q3-2026: Beat consensus by 39.7% - EPS $-7.56 vs $-12.5307 estimate

MORGAN STANLEY search volume spiked +46 pts - unusual interest

HARTFORD INSURANCE GROUP, INC. search volume spiked +100 pts - unusual interest

SHOPIFY INC. search volume spiked +60 pts - unusual interest

Callaway Golf Co search volume spiked +100 pts - unusual interest

People Inc search volume spiked +25 pts - unusual interest

CITIGROUP INC search volume spiked +100 pts - unusual interest

Q4-2026: Missed consensus by 9.4% - EPS $0.97 vs $1.0706 estimate

Q3-2025: Missed consensus by 37.9% - EPS $-0.75 vs $-0.544 estimate

Q3-2025: Missed consensus by 14.9% - EPS $-20.4 vs $-17.748 estimate

Q4-2025: Beat consensus by 10.2% - EPS $0.78 vs $0.708 estimate

Q3-2025: Beat consensus by 38.5% - EPS $0.55 vs $0.397 estimate

Q2-2024: Missed consensus by 152.8% - EPS $-1045.55 vs $-413.61 estimate

Q3-2023: Missed consensus by 33.8% - EPS $-43 vs $-32.13 estimate

Q4-2023: Beat consensus by 22.8% - EPS $-37 vs $-47.94 estimate

Q3-2024: Missed consensus by 139.3% - EPS $-277 vs $-115.77 estimate

Q1-2026: Missed consensus by 9.2% - EPS $2.5 vs $2.754 estimate

Q2-2020: Missed consensus by 34.6% - EPS $0.6 vs $0.918 estimate

Q3-2025: Missed consensus by 482.4% - EPS $-0.26 vs $0.068 estimate

Q1-2026: Missed consensus by 239.7% - EPS $-0.56 vs $0.401 estimate

Q1-2026: Missed consensus by 13.4% - EPS $1.06 vs $1.224 estimate

Q3-2025: Beat consensus by 10.3% - EPS $1.35 vs $1.224 estimate

Q1-2026: Missed consensus by 27.1% - EPS $43.9 vs $60.231 estimate

Q1-2026: Missed consensus by 7.3% - EPS $0.33 vs $0.356 estimate

VIX at 18.6: CAUTION territory